MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium
Atlanta, Georgia 30329
June 20-21, 2018

AGENDA ITEM                      PURPOSE                      PRESIDER/PRESENTER(s)

Wednesday, June 20
8:00    Welcome & Introductions

8:30    Influenza Vaccines
Introduction
VE update

     2017-2018 influenza season vaccine safety update
     Narcolepsy following adjuvanted monovalent pandemic H1N1
     influenza vaccines: Results of the SOMNIA study
     Study results of an adjuvanted Quadrivalent Influenza vaccine
     in young children
     2018-19 recommendations

Public Comment

     Vote

10:40   Break

11:00   Anthrax Vaccines
Introduction
GRADE
Summary of Work Group considerations and proposed policy
options

     Public comment

     Vote

12:15   Lunch

1:30    HPV Vaccines
Introduction
Current issues and background
HPV vaccine in mid-adults: results from clinical studies
Considerations and Work Group plans

     Information
     &
     Discussion

     Vote

2:40    Update on NITAGS
Introduction
Global NITAG activities and the GNN

     Information

     Vote

3:10    Break

3:40    Mumps Vaccine
Introduction
Current US mumps epidemiology and CDC guidance for
implementation of the ACIP recommendation for a 3rd dose of
MMR vaccine during outbreaks

     Information
     &
     Discussion

     Vote

4:10    Zoster Vaccine
Introduction
Herpes Zoster vaccination: evaluation update

     Information

     Vote

4:35    Public Comment

4:50    Adjourn
Thursday, June 21

8:00 Agency Updates & Unfinished Business
CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

8:30 Japanese Encephalitis Vaccine
Introduction
JE-VC GRADE
Comparative analysis background
Comparative analysis of JE vaccination strategies
Summary and conclusions

8:35 Break

11:00 Pneumococcal Vaccines
Introduction
Safety of PCV13 in adults aged >65 years old
Pneumonia Incidence in the US
Pneumococcal carriage, invasive disease, and hospitalizations following community acquired pneumonia (CAP) among Native American populations
Racial disparities in invasive pneumococcal disease and PCV13 impact
Overview of the Evidence to Recommendations Framework for the ongoing review of the PCV13 recommendation for adults ≥65 years old

12:30 Vaccine Supply

12:35 Public Comment

12:45 Adjourn

Acronyms
CDC Centers for Disease Control & Prevention
CMS Centers for Medicare and Medicaid Services
DoD Department of Defense
DVA Department of Veterans Affairs
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
HRSA Health Resources and Services Administration
IHS Indian Health Service
JE-VC Vero cell culture-derived Japanese encephalitis
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NCI National Cancer Institute
NIH National Institutes of Health
NITAG National Immunization Technical Advisory Groups
NVPO National Vaccine Program Office
PCV13 13-valent pneumococcal conjugate vaccine
VFC Vaccines for Children
WG Work Group
WHO IVB World Health Organization, Immunization, Vaccines and Biologicals